PDF(Pubmed)
Abstract：
BACKGROUND: Assessing vaccine willingness and understanding sources of vaccine hesitancy in individuals with multiple sclerosis (MS) helps healthcare providers approach patients more effectively while respecting their autonomy to encourage coronavirus disease 2019 (COVID-19) vaccination.
METHODS: A descriptive-analytical cross-sectional study using a researcher-made checklist was conducted on MS patients referred to Neshat Clinic of Hamadan during the years 2020-2021. The checklist contained questions about demographic information, MS phenotype, duration of illness, expanded disability status scale (EDSS) score, and COVID-19 vaccination status. The expanded disability status scale (EDSS) is the most commonly used instrument for measuring disability in patients with multiple sclerosis (MS). The EDSS scale ranges from 0 to 10 in increments of 0.5 units, denoting advanced points of disability.
RESULTS: Based on the results, 20 individuals (10%) were in the vaccine non-acceptance group, while 181 individuals (90%) were in the vaccine acceptance group. A significant number of relapsing and remitting (RR) type MS patients (90.7%) and all primary progressive (PP) type MS patients (100%) accepted the vaccine. In comparison, vaccine non-acceptance in the secondary progressive (SP) group was relatively higher (20.7%) compared to other types of MS, and this difference was significant (P < 0.05). Additionally, there was a statistically significant relationship between the history of COVID-19 and vaccine acceptance (P < 0.05).
CONCLUSIONS: The study results demonstrated a high rate of COVID-19 vaccine acceptance among MS patients. MS phenotype, previous infection experiences, and other influences allow for COVID-19 vaccine acceptance among MS patients. This information can improve health programs and communication strategies for COVID-19 and future possible infectious disease vaccination in individuals with MS.
METHODS: A descriptive-analytical cross-sectional study using a researcher-made checklist was conducted on MS patients referred to Neshat Clinic of Hamadan during the years 2020-2021. The checklist contained questions about demographic information, MS phenotype, duration of illness, expanded disability status scale (EDSS) score, and COVID-19 vaccination status. The expanded disability status scale (EDSS) is the most commonly used instrument for measuring disability in patients with multiple sclerosis (MS). The EDSS scale ranges from 0 to 10 in increments of 0.5 units, denoting advanced points of disability.
RESULTS: Based on the results, 20 individuals (10%) were in the vaccine non-acceptance group, while 181 individuals (90%) were in the vaccine acceptance group. A significant number of relapsing and remitting (RR) type MS patients (90.7%) and all primary progressive (PP) type MS patients (100%) accepted the vaccine. In comparison, vaccine non-acceptance in the secondary progressive (SP) group was relatively higher (20.7%) compared to other types of MS, and this difference was significant (P < 0.05). Additionally, there was a statistically significant relationship between the history of COVID-19 and vaccine acceptance (P < 0.05).
CONCLUSIONS: The study results demonstrated a high rate of COVID-19 vaccine acceptance among MS patients. MS phenotype, previous infection experiences, and other influences allow for COVID-19 vaccine acceptance among MS patients. This information can improve health programs and communication strategies for COVID-19 and future possible infectious disease vaccination in individuals with MS.
摘要：
背景：评估多发性硬化症（MS）患者的疫苗意愿并了解疫苗犹豫的来源，有助于医疗保健提供者更有效地接触患者，同时尊重他们的自主权，鼓励2019年冠状病毒病（COVID-19）疫苗接种。
方法：使用研究人员制作的清单对2020-2021年期间转诊至HamadanNeshat诊所的MS患者进行了描述性分析横断面研究。清单包含有关人口统计信息的问题，MS表型,疾病的持续时间,扩展残疾状况量表(EDSS)评分，和COVID-19疫苗接种状况。扩展残疾状况量表（EDSS）是测量多发性硬化症（MS）患者残疾的最常用工具。EDSS刻度范围从0到10，增量为0.5个单位，表示先进的残疾点。
结果：根据结果，20个人（10％）在疫苗不接受组中，而181名个体(90%)属于疫苗接受组。大量复发和缓解（RR）型MS患者（90.7％）和所有原发性进行性（PP）型MS患者（100％）接受了疫苗。相比之下,与其他类型的MS相比，次级进行性（SP）组的疫苗不接受度相对较高（20.7％），差异有统计学意义(P<0.05)。此外,COVID-19病史与疫苗接受度有统计学意义(P<0.05)。
结论：研究结果表明，MS患者接受COVID-19疫苗的比率很高。MS表型,以前的感染经历，和其他影响因素允许MS患者接受COVID-19疫苗。这些信息可以改善COVID-19的健康计划和沟通策略，以及MS患者未来可能的传染病疫苗接种。
方法：使用研究人员制作的清单对2020-2021年期间转诊至HamadanNeshat诊所的MS患者进行了描述性分析横断面研究。清单包含有关人口统计信息的问题，MS表型,疾病的持续时间,扩展残疾状况量表(EDSS)评分，和COVID-19疫苗接种状况。扩展残疾状况量表（EDSS）是测量多发性硬化症（MS）患者残疾的最常用工具。EDSS刻度范围从0到10，增量为0.5个单位，表示先进的残疾点。
结果：根据结果，20个人（10％）在疫苗不接受组中，而181名个体(90%)属于疫苗接受组。大量复发和缓解（RR）型MS患者（90.7％）和所有原发性进行性（PP）型MS患者（100％）接受了疫苗。相比之下,与其他类型的MS相比，次级进行性（SP）组的疫苗不接受度相对较高（20.7％），差异有统计学意义(P<0.05)。此外,COVID-19病史与疫苗接受度有统计学意义(P<0.05)。
结论：研究结果表明，MS患者接受COVID-19疫苗的比率很高。MS表型,以前的感染经历，和其他影响因素允许MS患者接受COVID-19疫苗。这些信息可以改善COVID-19的健康计划和沟通策略，以及MS患者未来可能的传染病疫苗接种。
